BACKGROUND: Virus-specific cellular immune responses mediated by CD4 and CD8 T lymphocytes are thought to be central to the effective control of HIV-1 replication in vivo. However, quantitative correlations between HIV-specific T lymphocyte frequencies and plasma virus load (pVL) have proved difficult to establish in infected human individuals. This most likely reflects the complex interactions between the virus and these immune effector cells in the absence of treatment. OBJECTIVE: To assess frequencies of HIV-specific T lymphocytes after prolonged suppression of viral replication, i.e., under conditions where the effects of virus on the immune response are standardized and minimized, thereby fixing an important variable in a dynamic multi...
OBJECTIVES: To analyze the dynamics of both HIV-1-specific CD4 and CD8 T-cell responses during struc...
Lymphoproliferative responses (LPRs) to recall antigens (Ags) and human immunodeficiency virus type ...
BACKGROUND: Highly active antiretroviral therapy (HAART) for human immunodeficiency virus (HIV)-1 in...
The potent ability of current antiretroviral drug regimens to control human immunodeficiency Virus-1...
The potent ability of current antiretroviral drug regimens to control human immunodeficiency Virus-1...
The potent ability of current antiretroviral drug regimens to control human immunodeficiency Virus-1...
International audienceThe influence of HIV burden variations on the frequencies of Ag-specific CD8+ ...
Human immunodeficiency virus type 1 (HIV-1)-infected subjects treated early after infection have pre...
Background: An increasing number of HIV-positive individuals now start antiretroviral therapy (ART) ...
Background: An increasing number of HIV-positive individuals now start antiretroviral therapy (ART) ...
Background. Studies aimed at defining the association between host immune responses and human immuno...
BACKGROUND: An increasing number of HIV-positive individuals now start antiretroviral therapy (ART) ...
Persons infected with human immunodeficincy virus (HIV) for > 8 years were studied to delinate vir...
OBJECTIVES: To assess whether drug-induced suppression of the plasma viral load is associated with s...
OBJECTIVE: HIV-specific cytotoxic T lymphocytes (CTL) are believed to play an important role in cont...
OBJECTIVES: To analyze the dynamics of both HIV-1-specific CD4 and CD8 T-cell responses during struc...
Lymphoproliferative responses (LPRs) to recall antigens (Ags) and human immunodeficiency virus type ...
BACKGROUND: Highly active antiretroviral therapy (HAART) for human immunodeficiency virus (HIV)-1 in...
The potent ability of current antiretroviral drug regimens to control human immunodeficiency Virus-1...
The potent ability of current antiretroviral drug regimens to control human immunodeficiency Virus-1...
The potent ability of current antiretroviral drug regimens to control human immunodeficiency Virus-1...
International audienceThe influence of HIV burden variations on the frequencies of Ag-specific CD8+ ...
Human immunodeficiency virus type 1 (HIV-1)-infected subjects treated early after infection have pre...
Background: An increasing number of HIV-positive individuals now start antiretroviral therapy (ART) ...
Background: An increasing number of HIV-positive individuals now start antiretroviral therapy (ART) ...
Background. Studies aimed at defining the association between host immune responses and human immuno...
BACKGROUND: An increasing number of HIV-positive individuals now start antiretroviral therapy (ART) ...
Persons infected with human immunodeficincy virus (HIV) for > 8 years were studied to delinate vir...
OBJECTIVES: To assess whether drug-induced suppression of the plasma viral load is associated with s...
OBJECTIVE: HIV-specific cytotoxic T lymphocytes (CTL) are believed to play an important role in cont...
OBJECTIVES: To analyze the dynamics of both HIV-1-specific CD4 and CD8 T-cell responses during struc...
Lymphoproliferative responses (LPRs) to recall antigens (Ags) and human immunodeficiency virus type ...
BACKGROUND: Highly active antiretroviral therapy (HAART) for human immunodeficiency virus (HIV)-1 in...